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Objective: in diabetic patients with critical limb ischaemia (CLI) an inferior success rate following infrainguinal bypass
surgery is quite often suggested. The aim of this retrospective analysis was, therefore, to evaluate the graft patency and,
particularly, the clinical outcome at 1 year in diabetic compared with non-diabetic patients.
Material and Methods: two hundred and eleven patients (diabetics 94; non-diabetics 117) with femorodistal reconstruc-
tion for CLI were studied. Groups were comparable with regard to the Fontaine classification, the distribution of vascular
risk factors, graft material, distal anastomosis site, and the angiographic runoff grading.
Results: diabetes did not adversely affect graft function. For diabetics and non-diabetics primary cumulative patency rate
at 1 year was found to be 66 and 56%, respectively (p 0.10) and a virtually identical limb salvage rate of 85 and 83% was
achieved (p 0.76). With regard to healing of ischaemic foot ulcers a trend against diabetics was noted with a healing rate
of 81% compared to 96% in non-diabetics at 1 year (p 0.067); gangrenous foot lesions could be equally remedied in 94%
and in 87% among patients with and without diabetes (p 0.44). The survival rate of diabetics, however, was significantly
lower with 78% at 1 year compared with 95% in non-diabetic patients (p 0.0004).
Conclusions: our preliminary results support the view that infrainguinal bypass grafting can be safely done even in
diabetics. Despite increased mortality in this group, liberal indication for reconstructive vascular surgery seems to be
justified by favourable patency rates and clinical outcome in selected patients.
Key Words: Femorodistal arterial reconstruction; Diabetes mellitus; Graft patency; Clinical outcome; Healing of pedal
lesions; Comparative study.
Introduction
During the last decade the frequency of femorodistal
reconstructions in diabetic patients presenting with
critical limb ischaemia (CLI) has rapidly increased.
In the meantime, the patency rates achieved in
contemporary studies hardly seem to differ in patients
with and without diabetes.1±4 Some series, however,
do report the clinical results to be worse in diabetic
patients, suggesting a lower limb salvage rate5±7 and
an increased mortality rate.3±5 Additionally, there
is almost no information on the postreconstructive
healing process of foot lesions that often appear
more extensively in diabetics.1 With this in mind, the
question arises whether infrainguinal reconstructions
are to be recommended to the group of diabetic
patients, especially since survival with a saved
functional limb is more and more regarded to be the
primary end point for the patient.8
To address this question whether patients with
diabetes really profit from revascularization during
the first postoperative year, we analysed data of a
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multicentre bypass study that, uniquely, provided
complete information on postreconstructive healing
of original pedal lesions. At first, in a comparative
evaluation this data was used to identify possible
differences in graft patency of femorodistal recon-
structions in diabetics and non-diabetics. In addition,
special emphasis was put on the analysis of clinical
end points, considering hereby the various limb
salvage rates, the healing progress of pedal defects,
as well as survival rates in both groups.
Material and Methods
In our evaluation we employed data prospectively
recorded for a randomized controlled trial (study
no. 88114; Schering AG, Berlin) that has not been
published to this point and was intended to examine
the benefit of adjuvant pharmacotherapy in femoro-
distal reconstructions. The control group forming the
basis to this retrospective analysis was drawn from
a total of 12 vascular surgical centres in Germany,
Austria, and Switzerland. Patients presenting with
chronic critical limb ischemia (Fontaine stages III and
IV) due to a lengthy occlusion of the superficial
femoral artery and the suprageniculate popliteal
artery were included. Not enrolled were patients
suffering from recent (less than 3 months) myocardial
infarction and stroke, respectively, as well as patients
in advanced renal failure (creatinine above 2.4 mg/dl).
Also, before the study began, the study design was
approved by the institutional ethic committee and
informed consent was obtained from each patient.
According to the study protocol, only patients
undergoing bypasses to the infrageniculate popliteal
artery or to crural arteries proximal to the ankle were
eligible for the study. In order to recruit cases with
compromised outflow tracts angiographic runoff
grading according to Rutherford9 was applied. A score
between 4 and 9 had to be present to be eligible.
Intraoperative quality control was mandatory using
completion angiography. After successful revascular-
ization, local wound treatment was continued and ± if
appropriate ± minor amputation was performed. Post-
operative antithrombotic therapy consisted initially of
intravenous heparin application for 3 weeks and was
switched to either platelet inhibitors or oral anticoa-
gulants depending upon the individual centre's pref-
erence. Graft patency and the clinical status patients
presented in, with emphasis on the healing progress
of their pedal lesions, were recorded postoperatively
after 14 days and after 3, 6, and 12 months.
In the statistical analysis, categorical and nominal
variables of two independent samples were compared
using the chi-square test and the test for difference of
proportions, respectively. Non-parametric variables
were analysed using the U-test according to Mann±
Whitney. All p-values given are two-tailed. The life-
table analysis of primary as well as of secondary graft
patency, limb salvage, and survival was performed in
compliance with Rutherford's guidelines.9 The log-
rank test was applied to evaluate statistically signifi-
cant differences between the subgroups. A stepwise
logistic regression model was used to determine the
possible influence of preoperative variables on
patency and survival.
Results
Eventually, 211 patients out of the 216 patients repre-
senting the control group of the study no. 88114
(Schering AG, Berlin) were analysed. All of their
data files remained complete until the end of the
study after the course of a year, or until death
occurred. Among the remainder of patients 94 were
found with and 117 without diabetes, the median age
being 71 (IQR 64±77) and 68 (IQR 61±76) years,
respectively (Table 1). The proportion of female
patients was significantly higher among diabetics.
Thus, both sexes were about evenly represented in
the diabetic group, whereas the distribution of sex in
the non-diabetic group showed a 3:1 domination of
males.
Patients with diabetes had suffered significantly
more often from myocardial infarction. However, no
relevant differences were found in regard to the pres-
ence of other comorbidities and the frequency of add-
itional atherogenous risk factors between diabetics
and non-diabetics. Also, angiographically determined
runoff scores according to Rutherford9 and the
Table 1. Demographic data.
Diabetics Non-diabetics p-value
Number of patients 94 117 ±
Males 53% 75% ±
Females 47% 25% 0.01
Age (median and range) 71 (64±77) 68 (61±76) n.s.
Fontaine stage III 19% 44% ±
Fontaine stage IV 81% 56% 0.002
Previous myocardial
infarction
11% 3% 0.03
Previous stroke 2% 5% n.s.
Hypertension 46% 37% n.s.
Hyperlipaemia 34% 24% n.s.
Smoker 60% 70% n.s.
Preoperative ankle
pressures (SEM) mmHg
60.1 (3.78) 57.8 (3.96) n.s.
Runoff grading9 (SEM) 6.56 (0.17) 6.63 (0.14) n.s.
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patients (Fig. 2), numbering 85 and 83% at 1 year,
respectively (log rank test: chi-square 0.09,
p 0.76).
After a fortnight early postoperative mortality was
found to be similar, with 2% in the diabetic group and
1% in the non-diabetic group (p 0.44). In contrast,
after a year had passed, the survival rate differed
significantly (Fig. 3) with a total of 78% in diabetic
patients and 95% in the non-diabetic ones (log rank
test: chi-square 12.62, p 0.0004).
The relationship of preoperative variables (age,
gender, Fontaine classification, history of myocardial
infarction, prior stroke, hypertension, hyperlipaemia,
smoking history, preoperative ankle pressures, and
angiographic runoff scores) and the outcome at one
year after surgery was analysed by using a stepwise
logistic regression model. In this regard, not any of the
above variables was associated with graft patency,
while increasing age (odds ratio 1.07; 95% CI 1.01±
1.13) and the presence of diabetes (odds ratio 3.93;
95% CI 1.45±10.62) emerged to be significant negative
determinants of survival.
Discussion
It is now generally accepted that diabetics do not have
an obstructive microangiopathy10 that precludes
femorodistal bypass grafting.11,12 Most series suggest
that the patency and limb salvage rate of infrainguinal
revascularization is similar in diabetic and non-
diabetic patients1±4,6,7,13±20 (Table 4). The present
study confirms this impression with comparable
results in the diabetic and non-diabetic cohorts.
Furthermore, the present study suggests that revascu-
larization in diabetic patients leads to healing of pedal
lesions in spite of a supposed immunopathy.21 In addi-
tion, with few exceptions,3,5 femorodistal bypass oper-
ations can be performed in diabetic patients as safely as
in non-diabetics with a perioperative mortality rate
below 5%. Nevertheless, further survival in diabetic
Table 3. Healing progress of ischaemic ulcer or gangrene in diabetic and non-diabetic patients from time of surgery until the end of the
first postoperative year.
Interval Time of
surgery (%)
ÿ14 days
postop. (%)
ÿ90 days
postop. (%)
ÿ180 days
postop. (%)
ÿ365 days
postop. (%)
p-value
Healing of ischaemic ulcer
Diabetics with ulcer 26 (100) 23 (88) 12 (46) 7 (27) 5 (19) Z 1.82; p 0.067
Non-diabetics with ulcer 28 (100) 26 (93) 7 (25) 2 (7) 1 (4)
Healing of gangrene
Diabetics with gangrene 18 (100) 11 (61) 2 (11) 1 (6) 1 (6) Z 0.77; p 0.44
Non-diabetics with gangrene 15 (100) 4 (27) 0 (0) 1 (7) 2 (13)
Fig. 2. Limb salvage rate following femorodistal reconstruction in diabetics and non-diabetics.
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actual function of the preserved foot and the duration
of healing achieved.
Acknowledgements
The authors are grateful to Schering AG, Germany, for generous
support.
References
1 Gahtan V, Harpavat M, Roberts AB, Kerstein MD. Impact
of diabetes mellitus on infrainguinal bypass grafting. J Diabetes
Comp 1988; 12: 197±200.
2 Hurley JJ, Auer AI, Hershey FB et al. Distal arterial reconstruc-
tion: Patency and limb salvage in diabetics. J Vasc Surg 1987; 5:
796±800.
3 Karacagil S, Almgren B, Bowald, S, Bergqvist D. Compara-
tive analysis of patency, limb salvage and survival in diabetic
and non-diabetic patients undergoing infrainguinal bypass
surgery. Diabetic Med 1995; 12: 537±541.
4 Stirnemann P, WuÈ rsten HU, Krebs Th. Langzeitergebnisse
nach infrainguinaler Arterienrekonstruktion bei Typ-II-
Diabetikern und Nicht-Diabetikern. Dtsch Med Wschr 1991; 116:
1175±1179.
5 Luther M. Treatment of chronic critical leg ischaemia ± a cost
benefit analysis. Ann Chir Gynaecol 1997; 86: 1±142.
6 Eugster T, Stierli P, Dittli U. Beeinfluût der Risikofaktor
Diabetes mellitus die Resultate der infrainguinalen arteriellen
Rekonstruktionen? GefaÈûchirurgie 1999; 4: 40±45.
7 Taylor LM, Edwards, JM, Porter JM. Present status of
reversed vein bypass grafting: Five-year results of a modern
series. J Vasc Surg 1990; 11: 193±206.
8 TransAtlantic Inter-Society Consensus (TASC). Manage-
ment of peripheral arterial disease. Eur J Vasc Endovasc Surg
2000; 19: S1±S250.
9 Rutherford RB, Baker JD, Ernst C et al. Recommended stan-
dards for reports dealing with lower extremity ischemia: Revised
version. J Vasc Surg 1997; 26: 517±538.
10 Goldenberg S, Alex M, Joshi RA, Blumenthal HT. Nonather-
omatous peripheral vascular disease of the lower extremity in
diabetes mellitus. Diabetes 1959; 8: 261±273.
11 Chantelau E. Obliterierende diabetische Mikroangiopathie am
diabetischen Fuû ± Tatsache oder Trugschluû. Z ges Innere Med
1993; 48: 376±380.
12 LoGerfo, FW, Coffman JD. Vascular and microvascular disease
of the foot in diabetes. N Engl J Med 1984; 311: 1615±1619.
13 Bergamini TM, Towne JB, Bandyk, DF, Seabrook GR,
Schmitt DD. Experience with in situ saphenous vein bypass
during 1981 to 1989: Determinant factors of long-term patency.
J Vasc Surg 1991; 13: 137±149.
14 Panneton JM, Gloviczki P, Bower TC, Rhodes JM, Canton LG,
Toomey BJ. Pedal bypass for limb salvage: Impact of diabetes on
long-term outcome. Ann Vasc Surg 2000; 14: 640±647.
15 Rosenblatt MS, Quist WC, Sidawy AN, Paniszyn CC,
LoGerfo FW. Results of vein graft reconstruction of the lower
extremity in diabetic and nondiabetic patients. Surg Gynecol
Obstet 1990; 171: 331±335.
16 Shah DM, Chang BB, Fitzgerald KM, Kaufman JL, Leather RP.
Durability of the tibial artery bypass in diabetic patients. Am J
Surg 1988; 156: 133±135.
17 Akbari CM, Pomposelli FB, Gibbons GW et al. Lower extremity
revascularisation in diabetes. Late observations. Arch Surg 2000;
135: 452±456.
18 Rutherford RB, Jones DN, Bergentz SE et al. Factors affecting
the patency of infrainguinal bypass. J Vasc Surg 1988; 8: 236±246.
19 Budd JS, Brennan J, Beard JD, Warren H, Burton PR, Bell PRF.
Infrainguinal bypass surgery: Factors determining late graft
patency. Br J Surg 1990; 77: 1382±1387.
20 Debus ES, Timmermann W, Sailer M, Schmidt K, Franke S,
Thiede A. Arterial reconstruction in diabetes and peripheral
arterial occlusive disease: results in 192 patients. VASA 1988; 27:
240±243.
21 Edmonds M, Bates M, Doxford M, Gough A, Foster A. New
treatments in ulcer healing and wound infection. Diabetes Metab
Res Rev 2000; 16: S51±S54.
22 Kalman PG, Johnston KW. Predictors of long-term patient
survival after in situ vein leg bypass. J Vasc Surg 1997; 25:
899±904.
23 Taylor LM, Porter JM. Results of lower extremity bypass in the
diabetic patient. Sem Vasc Surg 1992; 5: 226±233.
Accepted 3 December 2002
234 K. D. WoÈ lfle et al.
Eur J Vasc Endovasc Surg Vol 25, March 2003
